MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Roche Holding Company Profile (VTX:ROG)

Consensus Ratings for Roche Holding (VTX:ROG) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Roche Holding (VTX:ROG)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2015Morgan StanleyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Goldman SachsReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Roche Holding (VTX:ROG)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Roche Holding (VTX:ROG)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Roche Holding (VTX:ROG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Roche Holding (VTX:ROG)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Roche Holding (VTX:ROG)
DateHeadline
06/21/16 10:35 AMRogers Corp. – Value Analysis (NYSE:ROG) : June 21, 2016 -
06/07/16 08:56 AMRoche : Phase III study shows Roche’s Actemra/RoActemra maintained steroid-free remission in people with Giant Cell Arteritis (GCA)
06/06/16 07:13 AMRPT-Study finds targeted cancer drugs may work in range of tumor types - CHICAGO, June 4 (Reuters) - Early results from a clinical trial of Roche Holding AG cancer drugs released on Saturday suggest some promise in matching treatments based on abnormalities found in a...
05/31/16 07:06 AMRoche : First PT/INR home self-testing device with Bluetooth technology enabling remote care programmes for anticoagulated patients - CoaguChek INRange system enhances patient engagement with healthcare providers for optimal therapy management Roche (SIX: RO, ROG; OTCQX: RHHBY ... For more information, please visit www.roche.com. Roche Holding AG published this content on 30 May 2016 ...
05/18/16 01:04 PMU.S. FDA approves Roche's immunotherapy for bladder cancer - May 18 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Roche Holding AG's immunotherapy for the most common form of bladder cancer.
05/18/16 08:52 AMRogers Corporation to Participate in the B. Riley & Co.'s 17th Annual Investor Conference - [at noodls] - Home >> Investor Relations >> Latest News >> Rogers, Connecticut, May 18, 2016: Rogers Corporation (NYSE:ROG) will be participating in the Seventeenth Annual B. Riley & Co. Annual Conference ...
02/23/16 01:53 PMRoche Holding Ltd. (VTX:ROG)'s Company Shares Decreased 1.86% After High Volatility - Franklin Independent - Roche Holding Ltd. (VTX:ROG)'s Company Shares Decreased 1.86% After High VolatilityFranklin IndependentThe shares of Roche Holding Ltd. (VTX:ROG) decreased by 1.86% in the last 20 days but rose 2.13% in the past 5 trading sessions. Roche Holding Ltd. (VTX:ROG) shares opened at $45.77 in the last session and had intraday high of $46.51 and low of ...
02/03/16 11:15 AMRoche eyes acquisition of Pacific Biosciences: sources - Reuters - ReutersRoche eyes acquisition of Pacific Biosciences: sourcesReutersRoche Holding AG (ROG.VX) has in recent weeks approached Pacific Biosciences of California Inc (PACB.O) to discuss acquiring the U.S. company, spurred by interest in its advanced gene-sequencing technology, people familiar with the matter said.and more »
01/30/16 05:53 PMBristol-Myers set to lead earnings parade in 2016, beyond - Reuters - Bristol-Myers set to lead earnings parade in 2016, beyondReutersN) on Thursday predicted relatively flat 2016 earnings following strong gains last year, when sales of new cancer and diabetes drugs offset sharp declines in older medicines. Swiss rivals Roche Holding AG (ROG.VX) and Novartis AG (NOVN.VX) have also ...and more »
01/28/16 06:09 PMEUROPE MARKETS: European Stocks Finish Lower; Germany Hurt By Euro Strength - Nasdaq - EUROPE MARKETS: European Stocks Finish Lower; Germany Hurt By Euro StrengthNasdaqRoche Holding AG (ROG.VX) shares were shoved down 3.8% as the Swiss drugmaker's core net profit missed expectations (http://www.marketwatch.com/story/roche-profit-dented-by-strong-swiss-franc-2016-01-28-7485656). Growth is set to slow next year, ...and more »
01/28/16 06:09 PMEuropean stocks fall as earnings, Fed weigh - Morningstar.com - European stocks fall as earnings, Fed weighMorningstar.comRoche Holding AG (ROG.VX) shares were shoved down 4% as the Swiss drugmaker's core net profit missed expectations (http://www.marketwatch.com/story/roche-profit-dented-by-strong-swiss-franc-2016-01-28-7485656). Growth is set to slow next year, the ...and more »
01/28/16 06:09 PMBristol-Myers set to lead earnings parade in 2016, beyond - Reuters UK - Bristol-Myers set to lead earnings parade in 2016, beyondReuters UKN) on Thursday predicted relatively flat 2016 earnings following strong gains last year, when sales of new cancer and diabetes drugs offset sharp declines in older medicines. Swiss rivals Roche Holding AG (ROG.VX) and Novartis AG (NOVN.VX) have also ...and more »
01/28/16 10:59 AMEUROPE MARKETS: European Stocks Knocked Down, With Germany Hurt By Euro Strength - Nasdaq - EUROPE MARKETS: European Stocks Knocked Down, With Germany Hurt By Euro StrengthNasdaqRoche Holding AG (ROG.VX) shares were shoved down 4.4% as the Swiss drugmaker's core net profit missed expectations (http://www.marketwatch.com/story/roche-profit-dented-by-strong-swiss-franc-2016-01-28-7485656). Growth is set to slow next year, ...and more »
01/28/16 01:20 AMRoche FY15 Net Profit Down, But Sales Up; Sees Growth In FY16 - (RTTNews.com) - Swiss pharmaceutical giant Roche Holding AG ( RHHBY) Thursday reported a decline in fiscal 2015 profit while sales increased slightly. Looking ahead for fiscal 2016, the company projects group sales growth of low to mid-single digit and ...
01/27/16 05:54 PMInvesco European Growth Fund Adds to 7 Stakes - GuruFocus.com - Invesco European Growth Fund Adds to 7 StakesGuruFocus.comInvesco hiked its stake in Roche Holding AG (XSWX:ROG), a Basel, Switzerland-based pharmaceutical company, by more than 18%. Invesco purchased 13,668 shares for an average price of CHF262.25 (about $258.39 in U.S. currency) per share.
01/25/16 10:34 AMCompany Shares of Rogers Corporation (NYSE:ROG) Rally 3.09% - The Daily Rover - Company Shares of Rogers Corporation (NYSE:ROG) Rally 3.09%The Daily RoverRoche Holding AG (Roche) is a research-based healthcare company. The Companys operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Companys Pharmaceuticals Division comprises the two business segments: ...and more »
01/22/16 05:32 PMShares of Rogers Corporation (NYSE:ROG) Sees Large Outflow of Money - The Daily Rover - The Daily RoverShares of Rogers Corporation (NYSE:ROG) Sees Large Outflow of MoneyThe Daily RoverOn Aug 24, 2015, Carol R Jensen (director) sold 800 shares at 58.19 per share price.On Aug 11, 2015, Bruce D. Hoechner (CEO) purchased 800 shares at 58.88 per share price. Roche Holding Ltd. Last issued its quarterly earnings results on Oct 28, 2015.
11/28/15 05:59 PMTop Investors Losing Faith In Rogers Corporation (ROG) -
About Roche Holding

Roche Holding logoRoche Holding AG is a research-based healthcare company. The Company develops, manufactures and delivers medicines, and diagnostic instruments and tests. Its operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. Its Pharmaceuticals division consists of two business segments: Roche Pharmaceuticals and Chugai. Its Diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. It develops medicines for the disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its product portfolio consists of Pharmaceuticals, Solutions for Diagnostics and Products for Researchers. Its Pharmaceutical products include ACTEMRA and CellCept. Its Solutions for Diagnostics products include Accu-Chek Active System and Accu-Chek Aviva Nano System. The Company's Products for Researchers include Cedex HiRes and Genome Sequencer FLX System.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: VTX
  • Symbol: ROG
  • CUSIP:
Key Metrics:
  • Previous Close: $63.94
  • 50 Day Moving Average: $63.67
  • 200 Day Moving Average: $55.43
  • P/E Ratio: 23.51
  • P/E Growth: 1.18
  • Market Cap: $1.09B
  • Current Quarter EPS Consensus Estimate: $3.50 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha